Indication intelligence, analysis and sector perception

RegMed Investors (RMi) Research Note: Applied Genetic Technologies (AGTC)

November 15, 2022 12:02pm

The stock is trading at $0.39.09 (+0.72% or +$0.0028) as compared to tender offer of $0.34

A Syncona Limited portfolio company has commenced a tender offer to purchase all outstanding shares of AGTC common stock at a price per share of $0.34 in cash plus the right for AGTC stockholders to receive additional aggregate payments of up to $0.73 per share upon the achievement of specified milestones.

Investors NEED to tender; a NON vote will render the company bankrupt, liquidated and investors will get NOTHING!

The Bottom Line: Regardless of what investors think and feel that shareholders got ROBBED by CEO Susan Washer who also gets a $1.5 million dollar “walk-away” and pay-out after a 2022 comp package of $1.5 million.

Negating, Sue Washer’s $1.5 million payout should be a condition that the tender offer be completed.

She soldout investors by her incompetence with a massive employment contract gain !!

Additional thoughts … Georgeson LLC, the Information Agent has done a worse than terrible job in “marshalling” the tender contacting brokers not INVESTORS who ROUTINELY received corporate information – directly in the past – a “rope-a-dope”?

There are also multiple lawsuits that have been filed against the company for NOT supplying the full information regarding AGTC’s financial condition.

For the record, I am also an investor who was on the loosing end (and it wasn’t cheap); RegMed Investors (RMi) has been CEO Sue Washers biggest detractor and as many of us NOW feel – we should have dumped years ago when Biogen (BIIB) "walked".

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.